Postpartum Depression Market Analysis, Epidemiology Through 2034

DelveInsight's comprehensive "Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034" analysis delivers extensive understanding of Postpartum Depression, historical and projected epidemiology alongside market trends across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan.

For comprehensive details about the Postpartum Depression market perspective, drug adoption, treatment landscape and epidemiology patterns, Click here; Postpartum Depression Market Forecast https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Essential Insights from the Postpartum Depression Market Analysis

• The Postpartum Depression market dimension was estimated at approximately USD 260 million in 2023 across the 7MM countries and is expected to expand with substantial CAGR throughout the analysis timeframe (2020-2034).

• During July 2025, Biogen Inc. (Nasdaq: BIIB) disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has released a favorable opinion supporting marketing authorization for ZURZUVAE® (zuranolone) to manage postpartum depression (PPD) in adults following childbirth. If the European Commission (EC) provides approval, ZURZUVAE would establish itself as the first therapy in the EU specifically designated for depressive manifestations in women diagnosed with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment regimen, previously authorized by the U.S. FDA in 2023.

• During June 2025, Lipocine commenced dosing participants in its two-arm, blinded, randomized Phase III investigation evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD). This progression follows FDA guidance permitting the investigation to be performed in an outpatient environment, removing the necessity for continuous medical supervision. The organization anticipates utilizing the outcomes from this investigation to support a New Drug Application (NDA) submission scheduled for mid-2026.

• During March 2025, Lipocine launched a randomized Phase III clinical investigation for LPCN 1154, an oral formulation of brexanolone engineered to manage postpartum depression (PPD). The investigation follows a pharmacokinetic bridge study, which assessed LPCN 1154's exposure relative to the reference drug. The organization expects to dose the initial participant in the second quarter of this year.

• During May 2024, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical organization, disclosed the completion of subject dosing in the pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, an oral formulation of brexanolone, is under development as a treatment for postpartum depression (PPD).

• Across the EU4 countries and the UK, the UK demonstrated the largest market dimension for Postpartum Depression, valued at approximately USD 25 million in 2023.

• By 2034, ZURZUVAE is projected to generate approximately USD 600 million in revenue from the postpartum depression therapeutics marketplace across the 7MM.

• Across the EU4 countries and the UK, the UK maintained the largest postpartum depression market dimension, approximately USD 25 million in 2023.

• During 2023, Japan's postpartum depression market dimension was approximately USD 20 million, with moderate expansion anticipated by 2034.

• During 2023, the aggregate number of diagnosed postpartum depression cases across the seven major countries was approximately 1,310,000.

• During 2023, the aggregate number of diagnosed postpartum depression cases in the EU4 countries and the UK was approximately 460,000.

• During 2023, the United States demonstrated the highest number of diagnosed postpartum depression cases among the seven major markets, totaling approximately 720,000, followed by the UK.

• During 2023, Japan recorded approximately 126,000 diagnosed prevalent cases of postpartum depression.

• ZURZUVAE (zuranolone) and ZULRESSO (brexanolone) represent the only authorized treatments for postpartum depression (PPD). ZULRESSO is administered as a continuous intravenous (IV) infusion, while the recommended dosing for ZURZUVAE is 50 mg taken orally for 14 days. Leading organizations developing new PPD therapeutic agents include Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences.

• Leading Postpartum Depression Organizations: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, among others

• Primary Postpartum Depression Therapeutic Agents: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, among others

• The Postpartum Depression epidemiology assessment based on gender revealed that PPD predominantly affects females but a small proportion of males can also experience depression following pregnancy

• The Postpartum Depression marketplace is projected to experience substantial growth driven by rising disease prevalence and enhanced awareness throughout the projection timeframe. Additionally, the introduction of numerous multi-phase Postpartum Depression pipeline candidates will considerably transform the market landscape dynamics.

Postpartum Depression Disease Background

Postpartum depression (PPD) represents a complex emotional and psychological condition that impacts women following childbirth. It typically manifests within the initial few weeks to months after delivery and is marked by feelings of severe sadness, anxiety, and fatigue, which can substantially affect a mother's capacity to care for herself and her infant.

Access a complimentary sample for the Postpartum Depression Market Analysis: https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Postpartum Depression Epidemiology Analysis

The epidemiology segment delivers insights into historical, current, and projected epidemiology patterns across the seven major countries (7MM) from 2020 through 2034. It facilitates recognition of causes underlying current and forecasted patterns by examining multiple studies and perspectives of key opinion leaders. The epidemiology segment additionally provides comprehensive analysis of the diagnosed patient population and emerging trends.

Postpartum Depression Epidemiology Classification:

The Postpartum Depression market analysis presents epidemiological evaluation for the analysis period 2020-2034 across the 7MM categorized into:

• Total Prevalence of Postpartum Depression

• Prevalent Cases of Postpartum Depression by severity classification

• Gender-specific Prevalence of Postpartum Depression

• Diagnosed Cases of Episodic and Chronic Postpartum Depression

Access the analysis to comprehend which elements are influencing Postpartum Depression epidemiology patterns @ Postpartum Depression Epidemiology Forecast

Postpartum Depression Drug Adoption and Pipeline Activities

The drug adoption segment concentrates on the uptake velocity of potential therapeutic agents recently introduced in the Postpartum Depression marketplace or anticipated to launch during the analysis period. The evaluation encompasses Postpartum Depression market adoption by therapeutic agents, patient adoption by treatment modalities, and revenue of individual drugs.

Furthermore, the therapeutics evaluation segment facilitates understanding of drugs demonstrating the most accelerated adoption and underlying reasons for maximal utilization. Additionally, it compares therapeutic agents based on market penetration.

The analysis also encompasses the Postpartum Depression Pipeline Development Activities. It delivers valuable insights regarding various therapeutic candidates across multiple phases and primary organizations engaged in developing targeted therapies. It additionally analyzes recent advancements including collaborations, acquisitions, mergers, licensing patent information, and other intelligence for emerging therapeutic agents.

Postpartum Depression Therapeutic Agents and Leading Organizations

• Zuranolone(SAGE-217): SAGE Therapeutics

• BRII-296: Brii Biosciences Limited

• RE104: Reunion Neuroscience

• GH001: GH Research

• Brexanolone: Sage Therapeutics

• aripiprazole: Bristol-Myers Squibb

Postpartum Depression Market Growth Factors

• ZULRESSO initiates therapeutic action within 2-3 days of administration, substantially enhancing response rates compared to conventional treatment approaches

• Therapeutic agents like BRII-296 and LPCN-1154 are in preliminary phases of clinical development and their authorization in the future can facilitate tremendous growth in the PPD therapeutic marketplace.

Postpartum Depression Market Obstacles

• Restricted therapeutic options are available for managing and diagnosing PPD, thus creating profitable opportunities for investigational therapies

• Expanding research and development initiatives to establish the pathophysiology and recent progress in diagnosis provides a lucrative opportunity for the PPD marketplace

Coverage of the Postpartum Depression Market Analysis

• Analysis Period: 2020-2034

• Coverage: Global

• Leading Postpartum Depression Organizations: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, among others

• Primary Postpartum Depression Therapeutic Agents: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, among others

• Postpartum Depression Therapeutic Evaluation: Postpartum Depression current commercialized and Postpartum Depression investigational therapies

• Postpartum Depression Market Dynamics: Postpartum Depression market growth factors and Postpartum Depression market obstacles

• Competitive Intelligence Evaluation: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry methodologies

• Postpartum Depression Unmet Requirements, KOL perspectives, Analyst perspectives, Postpartum Depression Market Access and Reimbursement

Explore additional information about therapeutic agents positioned to capture significant Postpartum Depression market penetration @ Postpartum Depression Treatment Market

About DelveInsight

DelveInsight is a prominent Healthcare Business Consultant and Market Research organization focused exclusively on life sciences. It supports pharmaceutical companies by delivering comprehensive end-to-end solutions to enhance their performance.It additionally provides Healthcare Consulting Services, which contribute to market evaluation to accelerate business expansion and overcome obstacles with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com